Goodwin Procter LLP advised Rubius Therapeutics on the deal.Rubius Therapeutics (NASDAQ: RUBY) announced the upsized underwritten public offering of 6,896,552 shares of its common stock at a…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
